<![CDATA[Inotuzumab Ozogamicin Shows MRD Clearance in B-Cell ALL Trial]]>

<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>

<![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]>

<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>

<![CDATA[Pembrolizumab Plus EV Regimens Receive FDA Approval for Muscle Invasive Bladder Cancer]]>

Una combinación de medicamentos dirigidos produce remisiones duraderas en las personas con linfoma de células B de crecimiento rápido resistente al tratamiento

Los tumores de más de la mitad de los participantes que recibieron tratamiento con venetoclax, ibrutinib, prednisona, obinutuzumab y lenalid

Untitled

Telitacicept, a fusion protein targeting BAFF and APRIL, shows promise for IgA nephropathy in a phase 3 trial. Proteinuria ≥1.0 g/day addres